Clinical, pathological, and molecular correlates in ferroportin disease: A study of two novel mutations
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
BACKGROUND/AIMS: Clinico-pathological manifestations of ferroportin (Fpn) disease (FD) are heterogeneous, with some patients presenting with iron overload predominantly in macrophages ("M" phenotype), others predominantly in hepatocytes ("H" phenotype). This appears to reflect functional heterogeneity of Fpn mutants, with loss-of-function generally resulting in the M type. METHODS: Two unrelated probands with "non-HFE" hemochromatosis were screened for Fpn mutations. Mutants were functionally characterized by immunofluorescence microscopy, evaluation of their ability to bind hepcidin and export iron, and by expressing them in zebrafish. RESULTS: Two novel Fpn mutations were identified: I152F in patient-1, presenting with typical M phenotype; and L233P in patient-2, presenting with ambiguous features (massive overload in both macrophages and hepatocytes). Molecular studies suggested loss of function in both cases. The I152F, normally localized on cell membrane and internalized by hepcidin, showed a unique "primary" deficit of iron export capability. The L233P did not appropriately traffic to cell surface. Loss of function was confirmed by expressing both mutants in vivo in zebrafish, resulting in iron limited erythropoiesis. Clinical manifestations were likely enhanced in both patients by non-genetic factors (HCV, alcohol). CONCLUSIONS: The combination of careful review of clinico-pathological data with molecular studies can yield compelling explanations for phenotype heterogeneity in FD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004) · Cell · doi:10.1016/s0092-8674(04)00343-5 · Cited by 1,736
Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter
Donovan, A., Brownlie, A., Zhou, Y., Shepard, J., Pratt, S. J., Moynihan, J., Paw, B. H., Drejer, A., Barut, B., Zapata, A., et al. (2000) · Nature · doi:10.1038/35001596 · Cited by 1,667
Regulation of iron acquisition and storage: consequences for iron-linked disorders
De Domenico, I., McVey Ward, D., & Kaplan, J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2295 · Cited by 464 · cited 1×
“erythrocytes [2].”
Self-citationHepcidin in iron overload disorders
Papanikolaou, G., Tzilianos, M., Christakis, J. I., Bogdanos, D., Tsimirika, K., MacFarlane, J., Goldberg, Y. P., Sakellaropoulos, N., Ganz, T., & Nemeth, E. (2005) · Blood · doi:10.1182/blood-2004-12-4844 · Cited by 445 · cited 1×
“[26] reported high levels in two subjects carrying the Val162del mutation, subsequently placed into the loss-of-function category [11].”
Liver iron concentrations and urinary hepcidin in -thalassemia
Origa, R., Galanello, R., Ganz, T., Giagu, N., Maccioni, L., Faa, G., & Nemeth, E. (2007) · Haematologica · doi:10.3324/haematol.10842 · Cited by 365 · cited 1×
“Our data suggest that the inhibitory erythropoietic signal tends to prevail, which is in accordance with observations in HFE-HH phlebotomized patients and in other conditions of activated erythropoiesis [28].”
Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin
Drakesmith, H., Schimanski, L. M., Ormerod, E., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0561 · Cited by 264 · cited 1×
“At the opposite end of the spectrum are ‘‘gain-offunction” mutants that are properly localized on the membrane, but are resistant to hepcidin inactivation [11,15,16].”
Nishina, S., Hino, K., Korenaga, M., Vecchi, C., Pietrangelo, A., Mizukami, Y., Furutani, T., Sakai, A., Okuda, M., Hidaka, I., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2007.10.011 · Cited by 259
Ferroportin‐mediated mobilization of ferritin iron precedes ferritin degradation by the proteasome
De Domenico, I., Vaughn, M. B., Li, L., Bagley, D., Musci, G., Ward, D. M., & Kaplan, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601409 · Cited by 235 · cited 1×
“After FAC loading, cells were harvested, and ferritin content was determined by enzyme-linked immunosorbent assay (ELISA) as described previously [12].”
Self-citationThe molecular basis of ferroportin-linked hemochromatosis
De Domenico, I., Ward, D. M., Nemeth, E., Vaughn, M. B., Musci, G., Ganz, T., & Kaplan, J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503804102 · Cited by 230 · cited 4×
“Transfection of mutant Fpn constructs into different cell types has been successfully used to assess their functional behaviour [11].”
InfluentialSelf-citationHemochromatosis: An endocrine liver disease
Pietrangelo, A. (2007) · Hepatology · doi:10.1002/hep.21886 · Cited by 212 · cited 2×
“A number of clinical considerations are consistent with this view: (1) the TS, though high, was lower than expected considering the extreme elevation of serum ferritin and the degree of iron overload at diagnosis, suggesting a late TS increase similar to that previously reported by others [5]; (2) the MRI at diagnosis…”
In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations
Schimanski, L. M., Drakesmith, H., Merryweather-Clarke, A. T., Viprakasit, V., Edwards, J. P., Sweetland, E., Bastin, J. M., Cowley, D., Chinthammitr, Y., Robson, K. J. H., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4502 · Cited by 212 · cited 1×
“At the opposite end of the spectrum are ‘‘gain-offunction” mutants that are properly localized on the membrane, but are resistant to hepcidin inactivation [11,15,16].”
Cited by
Differential regulation of iron homeostasis during human macrophage polarized activation
Recalcati, S., Locati, M., Marini, A., Santambrogio, P., Zaninotto, F., De Pizzol, M., Zammataro, L., Girelli, D., & Cairo, G. (2010) · European Journal of Immunology · doi:10.1002/eji.200939889 · Cited by 438
Self-citationNramp1 promotes efficient macrophage recycling of iron following erythrophagocytosis in vivo
Soe-Lin, S., Apte, S. S., Andriopoulos, B., Andrews, M. C., Schranzhofer, M., Kahawita, T., Garcia-Santos, D., & Ponka, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900808106 · Cited by 167
Ferroportin disease: pathogenesis, diagnosis and treatment
Pietrangelo, A. (2017) · Haematologica · doi:10.3324/haematol.2017.170720 · Cited by 151
Ferroportin disease: a systematic meta-analysis of clinical and molecular findings
Mayr, R., Janecke, A. R., Schranz, M., Griffiths, W. J. H., Vogel, W., Pietrangelo, A., & Zoller, H. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.016 · Cited by 133
“It remains unclear whether L233V and D270P, each of which have been identified in single patients with iron overload, are disease-causing mutations or represent benign sequence variants [43,65].”
BackgroundNevitt, T., & Thiele, D. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1001322 · Cited by 95
“Two often contrasting clinical presentations observed in patients result from distinct mutations in Fpn that either abolish the hepcidin binding site or compromise Fe export, leading to differential effects on macrophage Fe levels [16,34,35,36].”
Background
Metadata
- Authors
- Girelli, D., De Domenico, I., Bozzini, C., Campostrini, N., Busti, F., Castagna, A., Soriani, N., Cremonesi, L., Ferrari, M., Colombari, R., McVey Ward, D., Kaplan, J., & Corrocher, R.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 49
- Issue
- 4
- Pages
- 664-671
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2024094127
- Cited by
- 42
- References
- 11
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.